Overview

Evaluation of the Response and Non-response of Nirogacestat in Desmoid Tumors- Clinical Study

Status:
Not yet recruiting
Trial end date:
2028-01-31
Target enrollment:
Participant gender:
Summary
To learn about the safety and effects of an investigational drug called nirogacestat when given to participants with a desmoid tumor/aggressive fibromatosis
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
SpringWorks Therapeutics, Inc.
Treatments:
Nirogacestat